Abstract
The global burden of type 2 diabetes is increasing worldwide, and successful treatment of this disease needs constant provision of new drugs. Twelve classes of antidiabetic drugs are currently available, and many new drugs are under clinical development. These include compounds with known mechanisms of action but unique properties, such as once-weekly DPP4 inhibitors or oral insulin. They also include drugs with new mechanisms of action, the focus of this review. Most of these compounds are in Phase 1 and 2, with only a small number having made it to Phase 3 at this time. The new drug classes described include PPAR agonists/modulators, glucokinase activators, glucagon receptor antagonists, anti-inflammatory compounds, G-protein coupled receptor agonists, gastrointestinal peptide agonists other than GLP-1, apical sodium-dependent bile acid transporter (ASBT) inhibitors, SGLT1 and dual SGLT1/SGLT2 inhibitors, and 11beta- HSD1 inhibitors.
Keywords: Antidiabetic drugs, new characteristics, new drug development, new insulins, new mechanisms of action, personalized medicine, type 2 diabetes.
Current Diabetes Reviews
Title:Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development
Volume: 11 Issue: 1
Author(s): Friedrich Mittermayer, Erica Caveney, Claudia De Oliveira, Loukas Gourgiotis, Mala Puri, Li-Jung Tai and J. Rick Turner
Affiliation:
Keywords: Antidiabetic drugs, new characteristics, new drug development, new insulins, new mechanisms of action, personalized medicine, type 2 diabetes.
Abstract: The global burden of type 2 diabetes is increasing worldwide, and successful treatment of this disease needs constant provision of new drugs. Twelve classes of antidiabetic drugs are currently available, and many new drugs are under clinical development. These include compounds with known mechanisms of action but unique properties, such as once-weekly DPP4 inhibitors or oral insulin. They also include drugs with new mechanisms of action, the focus of this review. Most of these compounds are in Phase 1 and 2, with only a small number having made it to Phase 3 at this time. The new drug classes described include PPAR agonists/modulators, glucokinase activators, glucagon receptor antagonists, anti-inflammatory compounds, G-protein coupled receptor agonists, gastrointestinal peptide agonists other than GLP-1, apical sodium-dependent bile acid transporter (ASBT) inhibitors, SGLT1 and dual SGLT1/SGLT2 inhibitors, and 11beta- HSD1 inhibitors.
Export Options
About this article
Cite this article as:
Mittermayer Friedrich, Caveney Erica, De Oliveira Claudia, Gourgiotis Loukas, Puri Mala, Tai Li-Jung and Turner J. Rick, Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development, Current Diabetes Reviews 2015; 11 (1) . https://dx.doi.org/10.2174/1573399810666141224121927
DOI https://dx.doi.org/10.2174/1573399810666141224121927 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sinus Node If Channel Inhibition – A New Therapeutic Approach to Heart Rate Lowering
Current Drug Therapy Ginger and Heart Health: From Mechanisms to Therapeutics
Current Molecular Pharmacology Aquaretic Agents: Whats Beyond the Treatment of Hyponatremia?
Current Pharmaceutical Design Laparoscopic Surgery for Pheochromocytoma and Paraganglioma Removal: A Retrospective Analysis of Anaesthetic Management
Current Hypertension Reviews The Role of Micafungin and Anidulafungin in the Treatment of Systemic Fungal Infections: Applications and Patents for Two Novel Echinocandins
Recent Patents on Anti-Infective Drug Discovery Anesthesia Issues in Central Nervous System Disorders
Current Aging Science Novel Monoclonal Antibodies for the Treatment of Chronic Lymphocytic Leukemia
Current Cancer Drug Targets Peptides for In Vivo Target-Specific Cancer Imaging
Mini-Reviews in Medicinal Chemistry Pathogenesis and Management of Hypertension after Kidney Transplantation
Current Hypertension Reviews Histamine and Histamine Receptor Antagonists in Cancer Biology
Inflammation & Allergy - Drug Targets (Discontinued) Classical Inhibitors of NOX NAD(P)H Oxidases Are Not Specific
Current Drug Metabolism Current Treatment of Autoimmune Blistering Diseases
Current Drug Discovery Technologies Purification and Characterization of a Novel Lectin with Antiphytovirus Activities from the wild Mushroom Paxillus involutus
Protein & Peptide Letters Targeting the Noradrenergic System in Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis of Prazosin Trials
Current Drug Targets Intrathecal Apelin-13 Produced Different Actions in Formalin Test and Tail-flick Test in Mice
Protein & Peptide Letters A Systematic Approach to Hypertensive Urgencies and Emergencies
Current Hypertension Reviews Treatment of Hypertension in Heart Failure with Preserved Ejection Fraction
Current Hypertension Reviews Role of Nitric Oxide in Ischemia and Reperfusion Injury
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Geriatric Depression - Review for Primary Care
Current Psychiatry Reviews Cannabinoids, Immune System and Cytokine Network
Current Pharmaceutical Design